Role of nitric oxide in the control of luteinizing hormone-releasing hormone release in vivo and in vitro. by V Rettori et al.
Proc. Natl. Acad. Sci. USA
Vol. 90, pp. 10130-10134, November 1993
Physiology
Role of nitric oxide in the control of luteinizing hormone-releasing
hormone release in vivo and in vitro
(plasma luteinizing hormone/NG-monomethyl-L-arglnlne/nitroprusside/hemoglobin/nitric oxide synthase)
V. RETToRI*, N. BELOVAt, W. L. DEESt, C. L. NYBERGt, M. GIMENO§, AND S. M. MCCANN*¶
*Neuropeptide Division, Department of Physiology, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX
75235-9040; tDepartment of Physiology, Medical Academy-Sofia, 1431 Sofia, Bulgaria; tDepartment of Veterinary Anatomy and Public Health, Texas A&M
University, Coliege Station, TX 77843-4458; and §Centro de Estudios Farmacologicos y Botanicos, Consejo Nacional de Investigaciones Cientificas y
Tecnicas, Serrano 665, 1414 Buenos Aires, Argentina
Contributed by S. M. McCann, July 26, 1993
ABSTRACT Nitric oxide (NO) synthase, the enzyme which
converts arginine into citrulline plus NO, a highly active free
radical, has been found in many neurons in the brain, including
neurons in the hypothalamus. Our previous experiments
showed that norepinephrine-induced prostaglandin E2 release
from hypothalamic explants incubated in vitro is mediated by
NO. Since the release of luteinizing hormone-releasing hor-
mone (LHRH) is also driven by norepinephrine and prostaglan-
din E2, we hypothesized that NO might also control pulsatile
release of LHRH in vivo, resulting in turn in pulsatile release
of luteinizing hormone (LH). To ascertain the role of NO in
control of pulsatile LH release in vivo, an inhibitor of NO
synthase, NG_monomethyl-L-arginine (NMMA), was microin-
jected into the third cerebral ventricle (1 mg/5 pi) of conscious
castrate male rats at time 0 and 60 min later; blood samples
were taken every 10 min during this period. NMMA blocked
pulsatile LH release within 20 min, and plasma LH concen-
tration declined further without pulses after the ij'ection at 60
min. Pulsatile release ofLH was not altered in diluent-injected
controls. NMMA did not alter pulsatile release of follide-
stimulating hormone, which suggests that its release does not
require NO. Incubation of medial basal hypothalami with
norepinephrine (10 pM) ind.uced an increase in LHRH release
that was inhibited by NMMA (300 PM). NMMA alone did not
alter basal LHRH release, whereas it was augmented by sodium
nitroprusside (100 FM), which releases NO spontaneously.
This augmentation was prevented by hemoglobin (2 jug/ml),
which binds the NO released by nitroprusside. Our previous
experiments showed that norepinephrine-induced release of
prostaglandin E2 is mediated by NO. Nitric oxidergic neurons
were visualized in the median eminence adjacent to the LHRH
terminals. The combined in vivo and in vitro results indicate
that the pulsatile release of LHRH induced by norepinephrine
is brought about by al-adrenergic activation of NO synthase.
NO then induces prostaglandin E2 release that activates exo-
cytosis of LHRH secretory granules into the portal vessels to
induce pulsatile LH release.
Nitric oxide (NO) released from vascular endothelium by
cholinergic stimulation diffuses to the adjacent vascular
smooth muscle and elicits relaxation (1-4). The mechanism
by which this occurs begins with the release of acetylcholine
from cholinergic terminals. It combines with muscarinic
cholinergic receptors on the endothelial cells and increases
intracellular Ca2+. The Ca2+ interacts with calmodulin to
activate constitutive NO synthase, which then converts
arginine into NO plus citrulline (1-4). Constitutive NO syn-
thase occurs in the brain (5, 6); this enzyme has been purified
and antibodies have been generated against it (7, 8). Neurons
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containing the constitutive NO synthase were found in var-
ious parts of the brain by immunocytochemistry (8); rela-
tively large numbers of these neurons occur in the paraven-
tricular and supraoptic nuclei of the hypothalamus (8).
These observations suggested a role for NO in hypotha-
lamic function, and we have previously reported that nore-
pinephrine-induced prostaglandin E2 (PGE2) release from
medial hypothalamic tissue incubated in vitro is mediated by
NO (9). Earlier reports associated this increase in PGE2
release with the release of luteinizing hormone-releasing
hormone (LHRH) (10-12). These observations raise the
possibility that NO mediates norepinephrine-induced LHRH
release.
Luteinizing hormone (LH) is released in a pulsatile fashion
in the living animal, and this release is caused by pulsatile
release of LHRH (13). Considerable evidence indicates that
norepinephrine acts via al-adrenergic receptors to induce
PGE2 release and consequent pulsatile release of LHRH
(10-12, 14). The LHRH is released into capillaries of the
hypophyseal portal veins and is carried to the hypophyseal
gonadotropes which release LH (14). Consequently, in the
present experiments we investigated the possible role ofNO
in the generation ofLHRH release in vitro and pulsatile LH
release in vivo. The results provide compelling evidence for
a crucial role forNO in the generation ofpulsatile LH release.
MATERIALS AND METHODS
All experiments utilized adult male rats of the Sprague-
Dawley strain (Holtzmann, Madison, WI) weighing 200-250
g. The in vivo studies utilized castrate males with increased
plasma concentrations of follicle-stimulating hormone (FSH)
andLH as a result ofremoval ofnegative feedback ofgonadal
steroids. The rats were castrated under ether anesthesia and
used for experiments 2-3 weeks later. Intact males were used
for the in vitro experiments. All rats were kept in group cages
in a light (0500 to 1900 hr) and temperature (23-25°C)-
controlled room with free access to laboratory chow and
water.
In Vivo Studies. Six to eight days prior to experiments an
indwelling cannula was implanted in the third cerebral ven-
tricle by the technique of Antunes-Rodrigues and McCann
(15) while the rats were anesthetized with tribromoethanol
given intraperitoneally. One day before the experiment an
indwelling catheter was introduced into the right externaljugular vein and advanced to the right atrium for collection of
blood samples according to the technique of Harms and
Ojeda (16). Immediately after collection of the first blood
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sample (0.3 ml), the test substances were microinjected into
the third ventricle in 5 Al of 0.9% NaCl (saline). Additional
(0.3 ml) blood samples were collected every 10 min for 120
min. An equal volume of saline was injected immediately
after removal of each sample to restore blood volume. In
certain animals NG-monomethyl-L-arginine (NMMA) (1 mg
in 5 ,ul of saline), an inhibitor of NO synthase, was microin-
jected into the third ventricle. NMMA or saline was micro-
injected over 60 sec. Sixty minutes after the first injection,
the animals which had received NMMA received a second
injection of the substance, whereas the control animals
received a second injection of saline.
After centrifugation, the plasma was stored frozen at
-20°C prior to radioimmunoassay for FSH and LH. LH was
assayed with the NIHRP3 standard and antiserum against
LH. FSH was assayed with the NIHRP2 standard and
antiserum against FSH. Both assay kits were provided by the
National Pituitary Agency (University of Maryland, Balti-
more).
In Yitro Studies. Following decapitation and removal of the
brain, the medial hypothalamus was dissected by making
frontal cuts just behind the optic chiasm, extending dorsally
2 mm. A horizontal cut extended from this point caudally to
just behind the pituitary stalk, where another frontal cut was
made. Longitudinal cuts were made 1 mm lateral to the
midline bilaterally. The hypothalami were preincubated in
Krebs-Ringer bicarbonate-buffered medium (pH 7.4) con-
taining 0.1% glucose for 30 min prior to replacement with
fresh medium or medium containing the substances to be
tested. The incubation was continued for 30 min followed by
removal of the medium and storage of samples at -20°C prior
to assay for LHRH. Incubations were carried out in a
Dubnoff metabolic shaker (50 cycles per min; 95% 02/5%
CO2) (9). LHRH was measured by radioimmunoassay using
highly specific LHRH antiserum kindly provided by A.
Barnea (University of Texas Southwestern Medical Center,
Dallas). The sensitivity of the assay was 0.2 pg per tube and
the curve was linear up to 100 pg of LHRH.
Chemicals used were norepinephrine, HC1, NMMA, so-
dium nitroprusside, and rat hemoglobin, all from Sigma.
Immunocytochemity ofNO Synthase. Adult male Sprague-
Dawley rats were anesthetized with equithesin, flushed with
Tris-buffered saline (TBS, pH 7.4) via cardiac perfusion, and
fixed with 4% paraformaldehyde. Brains were removed and a
block of hypothalamus from the optic chiasm to the rostral
border of the mammillary body was postfixed with the same
fixative for 24 hr. The tissues were washed in TBS and
Vibratome-sectioned at 40 ,uM. Free-floating sections of hy-
pothalamus containing the median eminence were incubated in
1% H202 for 60 min to remove any inherent peroxidase
activity. Sections were permeabilized with 0.4% Triton X-100
in TBS for 30 min then blocked with 4% normal goat serum
(NGS) for an additional 30 min. The tissues were incubated at
room temperature for 48 hr with affinity-purified antisera
directed against NO synthase, provided by S. H. Snyder and
T. M. Dawson (The Johns Hopkins University, Baltimore).
One antiserum was used at a dilution of 1:60 and the other at
1:100. Both antisera were diluted in TBS with 0.1% Triton
X-100 and 2% NGS and were absorbed at their respective
dilution- overnight with bovine serum albumin (BSA) at 500
pg/ml. Because BSA was used as the conjugate for the
production ofthese antisera, it was added to eliminate possible
false positive staining as a result of any residual anti-BSA
activity within the serum that could crossreact with albumin-
oid substances in the brain (17).
Following incubation in primary antiserum, the tissues
were washed in TBS with 1% NGS and incubated for 24 hr
at room temperature with biotinylated goat anti-rabbit im-
munoglobulin serum (Vector Laboratories) diluted 1:200 in
TBS with 1.5% NGS. The sections were then washed in TBS
with 1% NGS, washed in TBS, and incubated in ABC reagent
(Vector Elite) for 45 min. Tissues were washed in TBS
containing 3,3'-diaminobenzidine (0.5 mg/ml; Sigma) and
0.01% H202 for 2 min. After immunocytochemistry, all
sections were washed and mounted for observation at the
light microscopic level.
To ensure specificity of immunostaining, some sections
were incubated in primary antiserum absorbed 24 hr before
with BSA (as above), as well as purified NO synthase (200
,ug/ml; also a gift of S. H. Snyder). Additionally, for some
sections, TBS was substituted for the primary antiserum.
Statistics. Pulses were analyzed according to the method of
Cahoreau et al. (18). Areas under the plasma hormone curves
were calculated by trapezoidal integration. The results were
analyzed by one-way analysis of variance with repeated
measures and significance of differences was determined by
the Student-Newman-Keuls test. The differences between
the means of two groups were calculated by Student's t test.
RESULTS
In Vivo Experiments. Microinjection of saline into the third
cerebral ventricle did not alter mean plasma LH concentra-
tions or pulsatile LH release during the experiment (2 hr)
(Fig. 1). In striking contrast, the intraventricular injection of
NMMA caused a rapid cessation of pulsatile LH release, so
that no pulses were seen 30-50 min postinjection (Fig. 1).
However, in most animals plasma LH began to increase
slightly by 60-70 min postinjection. The second injection of
NMMA at 60 min induced a further decline in plasmaLH and
there were no LH pulses 80-120 min after the initial injection.
The height of the remaining LH pulses (8.9 ± 1.2 ag/ml, mean
+ SEM) was similar to controls (11.6 ± 2.3 ng/ml). The area
under the plasma LH curve was not decreased significantly
below that of the control animals in the first 60 min after
injection of NMMA (Fig. 2), because of the pattern just
described. However, it was significantly reduced during the
60-min period after the second injection of NMMA.
In contrast to the suppressive effect ofNMMA on pulsatile
LH release and mean plasma levels, pulsatile release ofFSH
was unaffected and the FSH pulses were frequently asyn-
chronous with those of LH (Fig. 3). The area under the
plasma FSH curve was not affected (data not shown).
In Vitro Studies. In the first experiment, the effects of
increasing NO concentration with sodium nitroprusside,
which spontaneously releases NO, and the effect of hemo-
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FIG. 1. Effect on the release of LH of microinjection of NMMA
(1 mg in 5 Al of saline) into the third ventricle (3V) of conscious
castrate male rats. An equal volume of saline was injected into the
3V of the control rats. NMMA or saline was injected a second time
at 60 min. There were six rats per group. Values in this and
subsequent figures are means ± SEM.
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FIG. 2. Area under the curve ofplasmaLH after third-ventricular
injection ofNMMA or saline in the rats whose plasma LH concen-
trations are illustrated in Fig. 1.
globin, a scavenger of NO, were evaluated. Nitroprusside
(100 uM) significantly increased LHRH release. Hemoglobin
(2 pjg/ml) had no effect on control release of LHRH but
completely abolished the effect of nitroprusside (Fig. 4).
In further experiments, NMMA (300 ,uM) had no effect on
control release ofLHRH; however, it completely blocked the
stimulatory effect of norepinephrine (10 ,uM) on LHRH
release (Fig. 5).
Loalization of Nitric Oxidergic Neurons. As reported pre-
viously (8), we observed NO synthase immunoreactivity in
the supraoptic and paraventricular regions of the hypothal-
amus. Additionally, we noted a few positive cells in the
lateral hypothalamic area, as well as numerous cells scattered
within the amygdaloid nucleus. Importantly, by using a
greater concentration of antiserum and longer incubation
times than in previous studies, we now report NO synthase
immunoreactivity in cells within the median eminence. These
cells were few in number and were not present in every
section; however, when present, they were most frequently
observed scattered in the dorsal and dorsolateral areas of the
internal layer ofthe median eminence,just ventral to the floor
of the third ventricle (Fig. 6). These NO synthase-containing
cells were observed with both antisera employed, and in each
case, positive staining in all regions of the hypothalamus,
including the median eminence, was eliminated by prior
absorption of the antiserum with purified NO synthase.
DISCUSSION
There is substantial evidence that the pulsatile release ofLH
is brought about by pulsatile release of LHRH that is driven
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FIG. 3. Effect ofmicroinjection ofNMMA into the third ventricle
(3V) ofconscious castrate male rats on the release ofFSH. These are
the same rats as in Fig. 1.
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FIG. 4. Effect of sodium nitroprusside (NP, 100 piM) or hemo-
globin (Hb, 2 pg/ml) on release of LHRH from the median basal
hypothalamus (MBH). There were six to eightMBH tubes per group.
P values are versus the NP group.
in turn by pulsatile release of norepinephrine; the latter acts
on ai-adrenergic receptors to induce LHRH release from
terminals of LHRH-secreting neurons in juxtaposition to
hypophyseal portal capillaries in the median eminence (15).
The LHRH that is released diffuses into hypophyseal portal
vessels and is transported to the pituitary, where it activates
the release of LH from the gonadotropes (15). Since micro-
injection of the NO synthase inhibitor NMMA into the third
cerebral ventricle decreased plasma LH and abolished LH
pulses, the data provide strong evidence that NO is essential
to generation of pulsatile LH release in vivo. NMMA did not
alter pulsatile FSH release, which suggests that the influence
of NO is specific for LHRH release and that hypothalamic
control over FSH is different from that over LH (19).
Considerable evidence indicates that control of FSH may be
mediated by another hypothalamic peptide, FSH-releasing
factor, which has yet to be isolated (20).
The in vitro experiments provide convincing evidence for
a role ofNO in the control of norepinephrine-induced LHRH
release: the generation of NO by nitroprusside enhanced
LHRH release, and the enhancement was abolished by a
scavenger of NO, hemoglobin. Because hemoglobin had no
effect on the basal release of LHRH, this suggests that this
unstimulated release does not require NO. Norepinephrine-
induced LHRH release was completely blocked by NMMA,
which again failed to alter control release. Thus, NO release
is essential for norepinephrine-induced LHRH release.
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FIG. 5. Effect of NMMA (300 ,uM) on norepinephrine (NE, 10
,uM)-stimulated LHRH release from the median basal hypothalamus
(MBH). There were six to eight MBH tubes per group. P values are
versus the NE group.
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FIG. 6. Section of rat hypothalamus demonstrating a few NO
synthase-positive cells (arrows) in the median eminence region. V,
third ventricle. (x900.)
Our previous experiments have demonstrated that norepi-
nephrine-induced PGE2 release is mediated by NO (9). Be-
cause norepinephrine-induced PGE2 release was implicated
in the release of LHRH by prior experiments from our
laboratory and others (10-12), it seemed logical that NO
might also mediate LHRH release. This hypothesis was
substantiated in the present experiments.
The mechanism by which norepinephrine operates to con-
trolLHRH release is conceptualized to involve three neurons
(Fig. 7). A norepinephrine terminal synapses with a NO-
releasing intemeuron (NOergic neuron) and makes an axo-
axonal synapse on an axon of a LHRH neuron which
terminates on a portal capillary. The norepinephrine neuron
perhaps arises from the locus coeruleus; lesions of the locus
coeruleus can block the preovulatory and pulsatile release of
LH (J. Franci and S.M.M., unpublished data). We hypoth-
esize that the norepinephrine terminal synapses on the NO-
ergic neuron, and on adjacent LHRH terminals, via al-
adrenergic receptors. The activation of each of these recep-
tors leads to conversion of inositol phosphates into inositol
trisphosphate. Inositol trisphosphate activates protein kinase
C, which liberates Ca2+ from intracellular stores. In the
NOergic neuron, the increased intracellular Ca2+ interacts
with calmodulin and activates the constitutive NO synthase
in this cell, which leads to generation of NO plus citrulline
(21). The NO diffuses across to the axon ofthe LHRH neuron
and activates cyclooxygenase by interaction with the heme
group on the enzyme (9). We have demonstrated herein the
presence of NOergic neurons in proximity to the LHRH
neuronal axons. The increased Ca2+ generated by the al-
adrenergic receptor combination with norepinephrine on the
LHRH axon activates phospholipase A2 to provide arachi-
donate from hydrolysis of membrane phospholipids. Arachi-
donate is then converted by activated cyclooxygenase to
PGE2, which activates adenylate cyclase, leading to an
increase in cyclic AMP and thus to activation of protein
kinase A, which induces exocytosis of LHRH secretory
granules.
FIG. 7. Schematic diagram of hypothetical interactions of nor-
epinephrine (NE) terminals with NOergic interneuron and LHRH
terminals to generate NO, PGE2, cyclic AMP, and LHRH release.
For detailed description, please see Discussion. Abbreviations: n
(suffix), neuron; mLipids, membrane phospholipids; AA, arachi-
donic acid; COX-HEME, cyclooxygenase; AC, adenylate cyclase;
ATP, adenosine triphosphate; NP, nitroprusside; Hb, hemoglobin;
citrul., citrulline; Cai, internal Ca2+; aR, al-adrenergic receptor;
PLA2, phospholipase A2; PV, portal vessel; +, stimulation or
increase; -, inhibition or decrease.
We believe that NO acts on the cyclooxygenase enzyme
rather than by its conventional mechanism-i.e., activation
of the soluble guanylate cyclase (21)-since the postulated
increase in intracellular Ca2+ in the LHRH terminal should
inhibit guanylate cyclase. That the cyclooxygenase enzyme is
activated is indicated by the ability of indomethacin, an
inhibitor of cyclooxygenase, to block the PGE2 and LHRH
release induced by norepinephrine (10).
We have recently obtained evidence for participation of
NO in other pathways within the hypothalamus. For exam-
ple, NO appears to mediate via activation of cyclooxygenase
the cholinergic and the interleukin-2-induced stimulation of
corticotropin-releasing factor release which is mediated by
cholinergic neurons within the hypothalamus (22). On the
other hand, growth hormone-releasing factor-induced so-
matostatin release via NO appears to be induced by activa-
tion of the guanylate cyclase pathway (23).
LHRH is the most important reproductive peptide known;
it plays a role not only in the release ofLH from the pituitary
but also in the induction of sexual behavior (14, 24). It follows
that NO might also be involved in mediation of sexual
behavior. Furthermore, NOergic neurons arising from the
anococcygeal region of the spinal cord innervate the bulbo-
cavernosa muscles of the penis. The release of NO causes
relaxation of their smooth muscle, allowing them to be filled
with blood and thus inducing the resultant penile erection (25,
26). Therefore, it appears that NO is extremely important to
reproduction at many levels in the organism.
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